UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
STOCK HUB · Updated September 19, 2026 · NASDAQ: QNCX
A pulmonary pipeline reset, with financing and listing complexity.
September 17: Quince scheduled a September 28 KOL webcast on LAM-001, PH-ILD and post-transplant BOS. This is a scientific discussion, not a promised new efficacy readout. Company announcement.
September 14 filing: the legacy Italian subsidiary, AIDE intellectual property and eDSP systems were sold to Ayma on September 8 for $450,000 cash. SEC 8-K.
Bull case: the pulmonary program has multiple clinical opportunities, while financing provides resources to pursue them. Execution and controlled evidence could strengthen the development case.
Bear case: early observations may not reproduce in larger studies. Listing uncertainty, preferred-stock conversion and warrants complicate the relationship between enterprise progress and value per common share.
September 28, 2026 · 12:30–2:00 p.m. ET: LAM-001 KOL event. The next corporate milestone is the October 6 stockholder meeting at 11:00 a.m. ET. Clinical-data windows remain company guidance, not guaranteed deadlines. Definitive proxy.
Open the QNCX daily stock chart on Finviz
External chart: Finviz. Quotes may be delayed. Historical prices and share counts must be read on a consistent split-adjusted basis.
Company: Quince Therapeutics, Inc. · Lead asset: LAM-001 · Focus: serious pulmonary diseases · Stage: clinical development; efficacy and regulatory approval remain unproven.
LAM-001 is investigational inhaled rapamycin, an mTOR inhibitor. PH-ILD development is in Phase 2b; BOS is in Phase 2, with enrollment complete. A SAPH Phase 2 start is planned for late 2026. These are development opportunities, not approved treatments. September pipeline update.
The former eDSP thesis should not be carried forward: the January NEAT trial missed its primary and key secondary endpoints, development was stopped, and the related assets have now been sold. Company news archive · Disposal filing.
At June 30, cash and equivalents were approximately $116 million. The May financing delivered $115 million gross / $103.6 million net. Management guided to funding through end-2028; that is a forecast. Potential warrant proceeds of up to $83 million are conditional and are not cash already received. Q2 net loss was $75.5 million and should not be equated with quarterly cash burn. Q2 financial release.
Allocation of proceeds; not current cash.
Source: Quince Q2 release, August 14, 2026
Two reporting-date snapshots. The increase includes financing; it is not operating cash generation.
Source: Quince Form 10-Q, June 30, 2026; filed August 14, 2026.
Quince completed 1-for-10 and 1-for-20 reverse splits in April and June. The June 30 Form 10-Q balance sheet reports 1,017,063 common shares outstanding. This is a dated basic count, not a fully diluted denominator. The earnings release gives a different share figure; this hub uses the filed balance sheet. Series C preferred stock and warrants make a common-share-only valuation incomplete. Financial release · Form 10-Q.
The October 6 meeting includes transaction-related stockholder approvals. Review conversion terms and post-approval capitalization before relying on headline market capitalization or historical per-share comparisons. Proxy materials.
The August 31 Nasdaq notice cited negative stockholders’ equity of $35.324 million against a $10 million requirement. The company has until October 15 to submit a compliance plan; the notice did not immediately suspend trading. An extension depends on Nasdaq acceptance. A proposed move to the Nasdaq Capital Market and the name IRulya Therapeutics Inc., ticker IRLA, remain conditional on approvals. QNCX remains the identity used here as of this update. September 4 SEC filing.
Dirk Thye signed the latest 8-K as CEO. President Charles Ryan departed September 8, with a separation agreement disclosed in that filing. Governance is in transition alongside the business reset. Management disclosure.
Distinguish beneficial ownership, convertible securities and open-market insider transactions. This update does not infer insider buying from financing participation or assign an unverified ownership percentage. Ownership reference.
The competitive question is whether pulmonary delivery can demonstrate a clinically meaningful benefit with acceptable safety. Mechanistic rationale alone is insufficient. No current analyst consensus, social-sentiment score or price target is assigned without a verified, dated dataset.
Constructive: corporate approvals, progress toward listing compliance and credible controlled evidence.
Intermediate: development proceeds while investors await data and clarification of dilution.
Adverse: disappointing efficacy or tolerability, delays, listing difficulties or financing terms that weaken per-share economics. These are qualitative scenarios, not probabilities or price forecasts.
Health Score: not assigned. Capitalization and listing status are in transition; a single numerical score would obscure unresolved inputs.
QNCX should be evaluated as a pulmonary clinical-development company undergoing a corporate reset. The central questions are evidence quality, execution, listing resolution and dilution.
Clinical timing is company guidance. The company announcement is the primary source for the webcast; corporate-event terms are documented in SEC filings.
For educational and informational purposes only. This is not investment advice or a recommendation to buy or sell securities. Clinical-stage biotechnology and corporate restructuring involve substantial risk.
